{
  "abstract": "Artificial intelligence (AI) is increasingly used for the discovery, development and delivery of pharmaceutical products. Between 2016 and 2023, the US Food and Drug Administration received over 300 submissions for registration of medicines with AI components.1",
  "authors": [
    {
      "affiliations": [
        "Research for Health, World Health Organization, Geneva, Switzerland"
      ],
      "name": "Rohit Malpani"
    },
    {
      "affiliations": [
        "Department of Health Products Policy and Standards, World Health Organization, Geneva, GE, Switzerland"
      ],
      "name": "Deirdre Dimancesco"
    },
    {
      "affiliations": [
        "Department of Digital Health and Innovation, World Health Organization, Geneva, GE, Switzerland"
      ],
      "name": "Sameer Pujari"
    },
    {
      "affiliations": [
        "Research for Health, World Health Organization, Geneva, Switzerland"
      ],
      "name": "Andreas Reis"
    }
  ],
  "title": "Can the use of AI in the pharmaceutical sector deliver new medicines, not new risks?",
  "uid": "a86d4add-972f-55e9-ae60-c6433fa5f49a"
}